AA
CLYM

ALPS Advisors’s Climb Bio CLYM Stock Holding History

ALPS Advisors’s Portfolio CLYM Stock Details CLYM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$758K Buy
+58,121
New +$600K ﹤0.01% 778

Other funds holding CLYM

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
NFT
Nan Fung Trinity Central, Hong Kong, Hong Kong $1.01B AUM 64.38% 1-Year Est. Return
TD Asset Management
TD Asset Management Toronto, Ontario, Canada $115B AUM 41.58% 1-Year Est. Return
Fifth Third Bancorp
Fifth Third Bancorp Cincinnati, Ohio $61.7B AUM 33.76% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return
OC
Oppenheimer & Co New York $9.37B AUM 36.4% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return

ALPS Advisors's CLYM Position: Q2 2026 in Review

ALPS Advisors opened a new position in Climb Bio (CLYM) in Q2 2026: 58,121 shares worth $758K. The stake represents ﹤0.01% of the portfolio and ranks #778 among its holdings.

22 funds tracked by Wall St. Rank hold CLYM as of Q2 2026.

  • ALPS Advisors held 58,121 shares of Climb Bio worth $758K as of Q2 2026.
  • Climb Bio was a new ALPS Advisors position in Q2 2026.
  • Climb Bio made up ﹤0.01% of ALPS Advisors's portfolio in Q2 2026, its #778 holding.
  • 22 funds tracked by Wall St. Rank held Climb Bio as of Q2 2026.

Based on ALPS Advisors's 13F filing for Q2 2026, filed 29 Jul 2026.